Neurocrine Biosciences Intangible Amortization decreased by 90.9% to $100.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 90.0%, from $1.00M to $100.00K.
An increase often follows a period of aggressive M&A activity, reflecting the cost of integrating acquired intellectual property.
This metric tracks the systematic write-down of the value of acquired intangible assets, such as patents, trademarks, an...
Common in companies with high M&A activity; peers in the medical device sector typically show consistent levels.
amortization_of_intangibles| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $500.00K | $900.00K | $900.00K | $900.00K | $800.00K | $900.00K | $900.00K | $900.00K | $900.00K | $1.00M | $1.00M | $1.00M | $1.10M | $100.00K |
| QoQ Change | — | — | — | — | — | — | — | +80.0% | +0.0% | +0.0% | -11.1% | +12.5% | +0.0% | +0.0% | +0.0% | +11.1% | +0.0% | +0.0% | +10.0% | -90.9% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | +60.0% | +0.0% | +0.0% | +0.0% | +12.5% | +11.1% | +11.1% | +11.1% | +22.2% | -90.0% |